TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03411837

Intervention type: BIOLOGICAL
Intervention: Dupilumab
Description: Biologic (monoclonal antibody)
Study: NCT00539721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
Study: NCT04520269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: 3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
Study: NCT00539721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Study: NCT00174941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
Study: NCT04952012

Intervention type: DRUG
Intervention: LT4
Description: LT4 is used to improve the thyroid function of pregnant women.

Intervention type: DRUG
Intervention: LT4
Description: LT4 is used to improve the thyroid function of pregnant women.
Study: NCT05784792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lugol -
Description: Patients that undergo total thyroidectomy without Lugol solution pretreatment
Study: NCT04763265

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A BoNT/A-DP
Description: To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A Botox Cosmetics
Description: To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.
Study: NCT01755481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Study: NCT00283712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo administered in place of infliximab for control group
Study: NCT02429648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCC first then PVI
Description: DCC performed prior to PVI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI then DCC after
Description: DCC performed after PVI, if patient remains in Atrial Fibrillation
Study: NCT03126227

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101
Description: AR101 powder provided in capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder provided in capsules
Study: NCT04252417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: Single oral dose administration of MD1003 at Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD1003
Description: Single oral dose administration of MD1003 at Day 1
Study: NCT01598181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS NeuroConn DC-stimulator plus
Description: Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS NeuroConn DC-stimulator plus
Description: Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: similar montage and time as active. Stimulation fades out after 20 sec.
Study: NCT03569007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Larazotide
Description: Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Larazotide
Description: Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
Study: NCT03273153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg as IV infusion once in every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
Study: NCT02012335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECT + Ketamine
Description: Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
Study: NCT03004703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
Study: NCT00819312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YAZ (SH T00186, BAY86-5300)
Description: 20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Study: NCT03542669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6B11-OCIK Injection
Description: Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
Study: NCT00636129

Intervention type: BEHAVIORAL
Intervention: Relaxation Response + Stress Management Curriculum
Description: Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
Study: NCT00264108

Intervention type: DRUG
Intervention: Darbepoetin alfa
Description: Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.

Intervention type: DRUG
Intervention: Epoetin alfa
Description: 40,000 IU once weekly, variable treatment length.
Study: NCT01537887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally once daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose administered orally.
Study: NCT03559569

Intervention type: BIOLOGICAL
Intervention: Biological samples will be done to evaluate the endothelial and leukocyte senescence.
Description: Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.

Intervention type: BIOLOGICAL
Intervention: Biological samples will be done to evaluate the endothelial and leukocyte senescence.
Description: Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
Study: NCT03537482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 will be administered as an oral tablet
Study: NCT00834275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg Capsules
Description: 1 x 500 mg
Study: NCT00217438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amifostine trihydrate
Description: Given IV
Study: NCT00834275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DURICEF® capsules 500 mg
Description: 1 x 500 mg
Study: NCT03599362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Cabiralizumab
Description: Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
Study: NCT05456763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium butyrate
Description: add-on therapy irrespective of standard treatment depending on severity (according to the guidelines)
Study: NCT03569007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: enteric-coated beads in gelatin capsules
Study: NCT03144635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir plus Elbasvir
Description: An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
Study: NCT01716156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
Study: NCT05456763

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04547192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving initial care of the injured
Description: Improvement in Care Processes
Study: NCT00798603

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT02742558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cholvax
Description: Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
Study: NCT04049760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study: NCT02466451

Intervention type: OTHER
Intervention: Questionnaires
Description: For not collaborative patients, under the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~* Standardized questionnaire collecting anamnestic-clinical data~* Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~* Spirometry~* 6-minutes walk test (WT 6')~* Prick tests~* Children Quality of life questionnaire (KINDL questionnaire)~* Psychological test (Raven Matrices)~* Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)
Study: NCT04183335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizers
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT00217438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study: NCT04183335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low to medium potent topical corticosteroids
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcineurin inhibitors
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT03827395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEV 239
Description: Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 \[4.5 - 7.0\]).
Study: NCT04193241

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of chest tube wound
Description: At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of chest tube wound
Description: At the time of chest tube removal, the chest tube site or thoracostomy wound will be closed in such a way as to prevent an iatrogenic pneumothorax or contamination of the pleural space
Study: NCT03934281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honey dressing Melectis G
Description: The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HAS recommendation dressing
Description: Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended.
Study: NCT00988715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pretargeted Radioimmunotherapy
Description: Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT00217438

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative study
Study: NCT00988715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01942122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1442 100
Description: Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid
Description: Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1442 200
Description: Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
Study: NCT05150041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian connect
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian connect
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPro2
Description: * Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.~* Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
Study: NCT03607253

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive heel rise activity
Description: Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive heel rise activity
Description: Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
Study: NCT00741780

Intervention type: DRUG
Intervention: Placebo

Intervention type: DRUG
Intervention: plerixafor

Intervention type: DRUG
Intervention: granulocyte colony-stimulating factor (G-CSF)

Intervention type: DRUG
Intervention: granulocyte colony-stimulating factor (G-CSF)
Study: NCT05615909

Intervention type: RADIATION
Intervention: Online MR-guided radiotherapy
Description: Online adaptive MR-guided radiotherapy in the Unity MR-linac for localized intermediate risk prostate cancer (60 Gy/20 fx) or low-volume metastatic prostate cancer (36 Gy/6 fx).

Intervention type: RADIATION
Intervention: CT-guided radiotherapy
Description: CT-guided radiotherapy in linear accelerators for patients with high-risk prostate cancer (78 Gy/39 fx), intermediate risk prostata cancer (60 Gy/20 Fx) or having salvage radiotherapy (70 Gy/35 fx)
Study: NCT00217438

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: fluorescence in situ hybridization
Description: Correlative study
Study: NCT01148186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: knowledge transfer tool
Description: knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
Study: NCT00217438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Undergo transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow ablation with stem cell support
Description: Undergo transplant